EP1001764A4 - Composes d'amide heterocycliques utilises en tant qu'inhibiteurs de l'adhesion cellulaire - Google Patents

Composes d'amide heterocycliques utilises en tant qu'inhibiteurs de l'adhesion cellulaire

Info

Publication number
EP1001764A4
EP1001764A4 EP98926122A EP98926122A EP1001764A4 EP 1001764 A4 EP1001764 A4 EP 1001764A4 EP 98926122 A EP98926122 A EP 98926122A EP 98926122 A EP98926122 A EP 98926122A EP 1001764 A4 EP1001764 A4 EP 1001764A4
Authority
EP
European Patent Office
Prior art keywords
cell adhesion
amide compounds
adhesion inhibitors
heterocyclic amide
heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP98926122A
Other languages
German (de)
English (en)
Other versions
EP1001764A1 (fr
Inventor
Philippe L Durette
William K Hagmann
Malcolm Maccoss
Sander G Mills
Richard A Mumford
Gail M Van Riper
Jack A Schmidt
Nancy J Kevin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9714314.3A external-priority patent/GB9714314D0/en
Priority claimed from GBGB9800686.9A external-priority patent/GB9800686D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1001764A1 publication Critical patent/EP1001764A1/fr
Publication of EP1001764A4 publication Critical patent/EP1001764A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP98926122A 1997-05-29 1998-05-29 Composes d'amide heterocycliques utilises en tant qu'inhibiteurs de l'adhesion cellulaire Ceased EP1001764A4 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US4801797P 1997-05-29 1997-05-29
US48017P 1997-05-29
GB9714314 1997-07-07
GBGB9714314.3A GB9714314D0 (en) 1997-07-07 1997-07-07 Heterocyclic amide compounds as cell adhesion inhibitors
US6652597P 1997-11-25 1997-11-25
US66525P 1997-11-25
GB9800686 1998-01-14
GBGB9800686.9A GB9800686D0 (en) 1998-01-14 1998-01-14 Hetrocyclic amide compounds as cell adhesion inhibitors
PCT/US1998/010940 WO1998053814A1 (fr) 1997-05-29 1998-05-29 Composes d'amide heterocycliques utilises en tant qu'inhibiteurs de l'adhesion cellulaire

Publications (2)

Publication Number Publication Date
EP1001764A1 EP1001764A1 (fr) 2000-05-24
EP1001764A4 true EP1001764A4 (fr) 2005-08-24

Family

ID=27451676

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98926122A Ceased EP1001764A4 (fr) 1997-05-29 1998-05-29 Composes d'amide heterocycliques utilises en tant qu'inhibiteurs de l'adhesion cellulaire

Country Status (4)

Country Link
EP (1) EP1001764A4 (fr)
JP (1) JP2002512625A (fr)
CA (1) CA2291778A1 (fr)
WO (1) WO1998053814A1 (fr)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053817A1 (fr) * 1997-05-29 1998-12-03 Merck & Co., Inc. Acide biarylalcanoique utilise en tant qu'inhibiteur de l'adhesion cellulaire
US6291511B1 (en) 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
JP2002501518A (ja) * 1997-05-30 2002-01-15 セルテック セラピューティックス リミテッド 抗炎症性チロシン誘導体
ES2206953T3 (es) 1997-06-23 2004-05-16 Tanabe Seiyaku Co., Ltd. Inhibidores de la adherencia celular mediada por alfa 4-beta 1.
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
DE69824037T2 (de) * 1997-11-24 2005-06-02 Merck & Co., Inc. Beta-alanin-derivate als zell-adhäsions-inhibitoren
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) * 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
US6555562B1 (en) 1998-02-26 2003-04-29 Celltech R&D Limited Phenylalanine derivatives
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6218423B1 (en) * 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
GB9828074D0 (en) 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
JP2002535314A (ja) 1999-01-22 2002-10-22 エラン ファーマシューティカルズ，インコーポレイテッド Ｖｌａ−４により媒介される白血球接着を阻害する化合物
MXPA01007394A (es) * 1999-01-25 2002-04-09 Wyeth Corp Compuestos que inhiben la adhesion de leucocitos mediada mediante alfa4 beta1 integrina y cd49d/cd29 (vla-4).
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
HUP0200155A3 (en) 1999-02-18 2005-04-28 Hoffmann La Roche Thioamide derivatives, pharmaceutical compositions containing them and their use
ID30057A (id) * 1999-02-18 2001-11-01 Hoffmann La Roche Turunan fenilalaninol
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
BR0012068A (pt) * 1999-06-30 2002-05-14 Daiichi Seiyaku Co Compostos inibidores de vla-4
US6756378B2 (en) 1999-06-30 2004-06-29 Pharmacopeia Drug Discovery, Inc. VLA-4 inhibitor compounds
PL354063A1 (en) 1999-08-13 2003-12-15 Biogen, Inc.Biogen, Inc. Cell adhesion inhibitors
WO2001012183A1 (fr) * 1999-08-16 2001-02-22 Merck & Co., Inc. Amides heterocycles comme inhibiteurs de l'adhesion cellulaire
EP1088821A1 (fr) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Derives des sulfamides pharmaceutiquement actifs
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
PT1237878E (pt) * 1999-12-06 2007-06-18 Hoffmann La Roche 4-pirimidinil-n-acil-fenilalaninas
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
KR100492111B1 (ko) * 1999-12-06 2005-06-01 에프. 호프만-라 로슈 아게 4-피리디닐-ｎ-아실-ｌ-페닐알라닌
DE60043308D1 (de) 1999-12-16 2009-12-24 Biogen Idec Inc Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
KR20020067050A (ko) 1999-12-28 2002-08-21 화이자 프로덕츠 인코포레이티드 염증성, 자기면역 및 호흡기 질환의 치료에 유용한브이엘에이-4 의존성 세포 결합의 비펩티드계 억제제
AU2001233069A1 (en) * 2000-01-28 2001-08-07 Biogen, Inc. Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses
WO2001068586A2 (fr) * 2000-03-14 2001-09-20 Novartis Ag INHIBITEURS D'INTEGRINES α4β1 ET α4β¿7?
WO2001079173A2 (fr) 2000-04-17 2001-10-25 Celltech R & D Limited Derives de l'enamine
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
WO2001098268A2 (fr) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Amides de piperidine utilises comme modulateurs de l'activite des recepteurs des chimiokines
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
EP1301488A1 (fr) 2000-07-07 2003-04-16 Celltech R&D Limited Derives d'acide squarique contenant un noyau heteroaromatique bicyclique comme antagonistes d'integrine
CA2417059A1 (fr) 2000-08-02 2002-02-07 Celltech R&D Limited Derives d'isoquinoline-1-yl substitues en 3
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
EP1193267A1 (fr) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Composés de sulfonamides hydrophiles pharmaceutiquement actifs
EP1193268A1 (fr) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Dérivés de sulfonamide pharmaceutiquement actifs comportant des groupes lipophiles ainsi que ionisables comme inhibiteurs de protéine junkinases
AU2001290303A1 (en) 2000-09-29 2002-04-15 Ajinomoto Co., Inc. Novel phenylalanine derivatives
JP2004526733A (ja) 2001-03-20 2004-09-02 メルク　エンド　カムパニー　インコーポレーテッド 強力な細胞接着阻害剤としての置換ｎ−アリールスルホニル−プロリン誘導体
US6559174B2 (en) 2001-03-20 2003-05-06 Merck & Co., Inc. N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors
US6855708B2 (en) 2001-03-20 2005-02-15 Merck & Co., Inc. N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors
AU2002351731A1 (en) 2001-12-14 2003-06-30 Novo Nordisk A/S Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
ES2197003B1 (es) * 2002-04-08 2005-03-16 J. URIACH & CIA S.A. Nuevos compuestos antagonistas de integrinas alfa.
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
JP4498133B2 (ja) 2002-07-02 2010-07-07 シェーリング コーポレイション 新規神経ペプチドｙｙ５レセプターアンタゴニスト
DE60230683D1 (de) 2002-07-08 2009-02-12 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
AU2003284984B2 (en) 2002-10-30 2008-10-23 Merck Sharp & Dohme Corp. Gamma-aminoamide modulators of chemokine receptor activity
MXPA05007823A (es) * 2003-01-24 2005-10-18 Elan Pharm Inc Composicion y tratamiento de enfermedades desmielizantes y paralisis por administracion de agentes remielinizantes.
EP1618091A1 (fr) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo hexane substitues en tant qu'antagonistes de recepteurs muscariniques
CN100436414C (zh) 2003-04-11 2008-11-26 兰贝克赛实验室有限公司 作为毒蕈碱受体拮抗剂的氮杂双环衍生物
UY28323A1 (es) 2003-05-21 2004-12-31 Boehringer Ingelheim Int Compuestos inhibidores de la hepatitis c
AU2004251750A1 (en) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
PE20050431A1 (es) 2003-09-22 2005-07-19 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
US20050176755A1 (en) * 2003-10-31 2005-08-11 Dyatkin Alexey B. Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
ES2358333T3 (es) 2004-01-21 2011-05-09 Boehringer Ingelheim International Gmbh Péptidos macrocíclicos con acción contra el virus de la hepatitis c.
WO2005070921A1 (fr) * 2004-01-23 2005-08-04 Elan Pharmaceuticals, Inc. Conjugues a base de polyethylene glycol d'acides heterocycloalkyl carboxamido propanoiques
BRPI0509803A (pt) 2004-04-13 2007-09-18 Incyte Corp derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina
JP2007533749A (ja) 2004-04-20 2007-11-22 アムゲン インコーポレイティッド アリールスルホンアミドおよびそれに関連する使用方法
US7777042B2 (en) 2004-06-29 2010-08-17 Aventis Pharmaceuticals Inc. N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof
DK1778637T3 (da) * 2004-06-29 2012-06-18 Aventis Pharma Inc FKBP-bindingssammensætninger og farmaceutisk anvendelse deraf
NZ588839A (en) * 2004-07-08 2012-09-28 Elan Pharm Inc Multivalent vla-4 antagonists comprising polyethylene glycol moieties
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
WO2006007708A1 (fr) 2004-07-20 2006-01-26 Boehringer Engelheim International Gmbh Analogues peptidiques inhibiteurs de l'hepatite c
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
US7618983B2 (en) 2004-11-10 2009-11-17 Janssen Pharmaceutica, N.V. Bicyclic triazole α4 integrin inhibitors
NZ567270A (en) 2005-09-29 2011-06-30 Elan Pharm Inc Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
CN101273035A (zh) 2005-09-29 2008-09-24 伊兰制药公司 抑制由vla-4介导的白细胞粘附的氨基甲酸酯化合物
MEP1008A (xx) 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
EA017110B1 (ru) 2006-02-27 2012-09-28 Элан Фамэсьютикэлс, Инк. ПИРИМИДИНИЛСУЛЬФОНАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ПОЛУЧЕНИЯ ПИРИМИДИНИЛСУЛЬФОНАМИДНЫХ СОЕДИНЕНИЙ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО ИНТЕГРИНОМ α4, СПОСОБ СНИЖЕНИЯ И/ИЛИ ПРЕДУПРЕЖДЕНИЯ ВОСПАЛИТЕЛЬНОГО КОМПОНЕНТА ЗАБОЛЕВАНИЯ ИЛИ АУТОИММУННОГО ОТВЕТА
AU2008219007A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
PL2288715T3 (pl) 2008-04-11 2015-03-31 Merrimack Pharmaceuticals Inc Łączniki będące albuminą surowicy ludzkiej i ich koniugaty
SI2370442T1 (sl) 2008-11-26 2013-06-28 Pfizer Inc. 3-aminociklopentankarboksiamidi kot modulatorji kemokinskega receptorja
US20100204221A1 (en) 2009-02-09 2010-08-12 Hariprasad Vankayalapati Pyrrolopyrimidinyl axl kinase inhibitors
WO2015048819A1 (fr) * 2013-09-30 2015-04-02 The Regents Of The University Of California Composés d'intégrine anti-aphavbêta1 et méthodes correspondantes
WO2016090403A1 (fr) * 2014-12-12 2016-06-16 Commonwealth Scientific And Industrial Research Organisation Détachement et libération de cellules souches hématopoïétiques à partir de niche de cellules souches de moelle osseuse au moyen d'antagonistes d'intégrine alpha-9
US10214522B2 (en) 2015-03-10 2019-02-26 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
EP3436046A4 (fr) * 2016-04-01 2020-03-11 The Regents of The University of California Inhibiteurs de l'intégrine alpha 5 bêta 1 et leurs procédés d'utilisation
WO2018140510A1 (fr) 2017-01-25 2018-08-02 Biogen Ma Inc. Composition et méthodes de traitement d'un accident vasculaire cérébral et d'autres troubles du snc
CN109111435B (zh) * 2017-06-26 2022-03-18 南京柯菲平盛辉制药有限公司 一类吡咯烷磺酰基衍生物RORγ调节剂及其用途
AU2019373245C1 (en) 2018-10-30 2022-10-27 Gilead Sciences, Inc. Compounds for inhibition of alpha 4β7 integrin
KR20240015737A (ko) 2018-10-30 2024-02-05 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
CA3115820A1 (fr) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Composes pour l'inhibition de l'integrine .alpha.4.beta.7
WO2020092394A1 (fr) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Dérivés d'imidazopyridine utilisés en tant qu'inhibiteurs de l'intégrine alpha4bêta7
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
KR20230038457A (ko) 2020-06-10 2023-03-20 알리고스 테라퓨틱스 인코포레이티드 코로나바이러스, 피코르나바이러스 및 노로바이러스 감염을 치료하기 위한 항바이러스 화합물
AU2022306289A1 (en) 2021-07-09 2024-01-18 Aligos Therapeutics, Inc. Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350698A (en) * 1981-09-25 1982-09-21 Smithkline Corporation Antiallergic imidosulfamides
EP0443132A1 (fr) * 1989-12-22 1991-08-28 Fujisawa Pharmaceutical Co., Ltd. Peptides ayant une activité antagoniste de tachykinine, leur préparation et médicaments les renfermant
EP0696593A2 (fr) * 1994-08-11 1996-02-14 Bristol-Myers Squibb Company Inhibiteurs de la farnesyl protéine transférase
WO1996040641A1 (fr) * 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. Derives de sulfonamides servant a moduler l'adherence cellulaire
WO1997021690A1 (fr) * 1995-11-28 1997-06-19 Cephalon, Inc. Inhibiteurs de cysteine et serine proteases derives d'acide d-amine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229381A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
IT1244873B (it) * 1990-09-12 1994-09-12 Depha Team Srl Derivati dell'acido 5-aminosalicilico (5-asa) per la terapia delle infiammazioni croniche intestinali
SE9300012D0 (sv) * 1993-01-05 1993-01-05 Astra Ab New peptides
CA2118985A1 (fr) * 1993-04-02 1994-10-03 Dinesh V. Patel Inhibiteurs heterocycliques de la farnesyl proteine transferase
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350698A (en) * 1981-09-25 1982-09-21 Smithkline Corporation Antiallergic imidosulfamides
EP0443132A1 (fr) * 1989-12-22 1991-08-28 Fujisawa Pharmaceutical Co., Ltd. Peptides ayant une activité antagoniste de tachykinine, leur préparation et médicaments les renfermant
EP0696593A2 (fr) * 1994-08-11 1996-02-14 Bristol-Myers Squibb Company Inhibiteurs de la farnesyl protéine transférase
WO1996040641A1 (fr) * 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. Derives de sulfonamides servant a moduler l'adherence cellulaire
WO1997021690A1 (fr) * 1995-11-28 1997-06-19 Cephalon, Inc. Inhibiteurs de cysteine et serine proteases derives d'acide d-amine

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BYK G ET AL: "Local constrained shifty pseudopeptides inhibitors of ras-farnesyl transferase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 5, no. 22, 16 November 1995 (1995-11-16), pages 2677 - 2682, XP004135213, ISSN: 0960-894X *
CALCAGNI A ET AL: "Peptides containing the sulfonamide junction: Synthesis, structure, and conformation of Z-Tau-Pro-Phe-NHiPr", BIOPOLYMERS 1997 UNITED STATES, vol. 41, no. 5, 1997, pages 555 - 567, XP002332346, ISSN: 0006-3525 *
HAGMANN W K ET AL: "The discovery of sulfonylated dipeptides as Potent VLA-4 antagonists", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS 22 OCT 2001 UNITED KINGDOM, vol. 11, no. 20, 22 October 2001 (2001-10-22), pages 2709 - 2713, XP002332349, ISSN: 0960-894X *
LIN L S ET AL: "Specific and dual antagonists of [alpha]4[beta]1 and [alpha]4[beta]7 integrins", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS 21 JAN 2002 UNITED KINGDOM, vol. 12, no. 2, 21 January 2002 (2002-01-21), pages 133 - 136, XP002332347, ISSN: 0960-894X *
LIN L S ET AL: "The discovery of acylated [beta]-amino acids as potent and orally bioavailable VLA-4 antagonists", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS 25 FEB 2002 UNITED KINGDOM, vol. 12, no. 4, 25 February 2002 (2002-02-25), pages 611 - 614, XP002332348, ISSN: 0960-894X *
See also references of WO9853814A1 *

Also Published As

Publication number Publication date
WO1998053814A1 (fr) 1998-12-03
CA2291778A1 (fr) 1998-12-03
JP2002512625A (ja) 2002-04-23
EP1001764A1 (fr) 2000-05-24

Similar Documents

Publication Publication Date Title
EP1001764A4 (fr) Composes d'amide heterocycliques utilises en tant qu'inhibiteurs de l'adhesion cellulaire
AU8059598A (en) Heterocyclic amide compounds as cell adhesion inhibitors
EP0998282A4 (fr) Sulfamides utilises en tant qu'inhibiteurs de l'adherence cellulaire
AU6903200A (en) Heterocycle amides as cell adhesion inhibitors
PL331795A1 (en) Heterocyclic metaloprotease inhibitors
EG24041A (en) New heterocyclic compounds
PL338259A1 (en) Novel spiroazabicyclic heterocyclic compounds
EP0743951A4 (fr) Derives de lactose substitues, utilises comme inhibiteurs de l'adhesion cellulaire
PL331856A1 (en) Heterocyclic inhibitors of metaloprotease
GB9715892D0 (en) Heterocyclic compounds
IL132170A0 (en) Novel heterocyclic compounds
HU9500655D0 (en) SULFATED BéTA-GLYCOLIPID DERIVATIVES AS CELL ADHESION INHIBITORS
IL127563A0 (en) Cell adhesion inhibiting compounds
AU1463499A (en) Substituted pyrrole derivatives as cell adhesion inhibitors
GB0017279D0 (en) Amides as cell adhesion inhibitors
ZA981920B (en) Novel heterocyclic compounds
HK1041270A1 (en) 2,-3-o-isoproylidene derivatives of monosaccharides as cell adhesion inhibitors
AU1176299A (en) Tryptase inhibitors comprising heterocyclic amide compounds
GB9706294D0 (en) Heterocyclic compound
AU5999698A (en) Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
GB9714314D0 (en) Heterocyclic amide compounds as cell adhesion inhibitors
GB9800686D0 (en) Hetrocyclic amide compounds as cell adhesion inhibitors
ZA985448B (en) Novel heterocyclic compounds
AU8731798A (en) Fused heterocyclic compounds and their use as kynurenine-3-hydroxylase inhibitors
GB9727215D0 (en) Substituted beta-alanine derivatives as cell adhesion inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991229

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 43/00 B

Ipc: 7A 61K 31/404 B

Ipc: 7C 07F 9/02 A

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/445 B

Ipc: 7A 61K 31/435 B

Ipc: 7A 61K 31/425 B

Ipc: 7A 61K 31/415 B

Ipc: 7A 61K 31/41 B

Ipc: 7A 61K 31/395 B

Ipc: 7A 61K 31/405 B

Ipc: 7C 07F 9/02 A

A4 Supplementary search report drawn up and despatched

Effective date: 20050711

17Q First examination report despatched

Effective date: 20051007

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20081004